Atlas Trials

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

Clinical trial NCT07705919 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07705919
Sponsor
Ohio State University Comprehensive Cancer Center
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Start date
2026-09-01
Primary completion
2027-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.